BioCentury
ARTICLE | Company News

Dainippon Sumitomo cancer news

October 21, 2013 7:00 AM UTC

Dainippon launched Boston Biomedical Pharma Inc. to focus on the commercialization of cancer therapies, including Dainippon's BBI608. The product, a small molecule targeting cancer stem cells, is in Phase III testing to treat colorectal cancer. Dainippon expects to launch the product in FY15, which ends March 31, 2016. Dainippon gained the compound through its 2012 acquisition of Boston Biomedical Inc. The subsidiary is headquartered in Cambridge, Mass. (see BioCentury, April 30, 2012). ...